



# MATERIAL SAFETY DATA SHEET

Revision date: 19-Oct-2010

Version: 2.0

Page 1 of 6

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-212-573-2222

Pfizer Ltd  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161  
Emergency telephone number:  
ChemSafe (24 hours): +44 (0)208 762 8322

Emergency telephone number:  
CHEMTREC (24 hours): 1-800-424-9300  
Contact E-Mail: pfizer-MSDS@pfizer.com

### Material Name: Epinephrine Solution for Injection

Trade Name: ADRENALIN  
Chemical Family: Not determined  
Intended Use: Pharmaceutical product used for allergic reactions (anaphylaxis)

## 2. HAZARDS IDENTIFICATION

**Appearance:** Clear colorless liquid

**Statement of Hazard:** Non-hazardous in accordance with international standards for workplace safety.

**Additional Hazard Information:**  
**Short Term:** May be absorbed through the skin and cause systemic effects. May be absorbed through mucous membranes and cause systemic effects.

**Known Clinical Effects:** Adverse effects associated with therapeutic use include increased heart rate (tachycardia), palpitations, sweating, nausea, vomiting, difficulty breathing, dizziness, weakness, headache, anxiety, nervousness.

**EU Indication of danger:** Not classified

**Australian Hazard Classification (NOHSC):** Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

### Hazardous

| Ingredient | CAS Number | EU EINECS/ELINCS List | EU Classification | % |
|------------|------------|-----------------------|-------------------|---|
|------------|------------|-----------------------|-------------------|---|

## MATERIAL SAFETY DATA SHEET

Material Name: Epinephrine Solution for Injection  
Revision date: 19-Oct-2010

Page 2 of 6  
Version: 2.0

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

|                  |           |           |               |     |
|------------------|-----------|-----------|---------------|-----|
| Epinephrine      | 51-43-4   | 200-098-7 | T;R24/25      | 1.0 |
| Sodium bisulfite | 7631-90-5 | 231-548-0 | R31<br>Xn;R22 | *   |

| Ingredient          | CAS Number | EU EINECS/ELINCS List | EU Classification | % |
|---------------------|------------|-----------------------|-------------------|---|
| Water for Injection | 7732-18-5  | 231-791-2             | Not Listed        | * |
| Sodium chloride     | 7647-14-5  | 231-598-3             | Not Listed        | * |

**Additional Information:** Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Measures for Environmental Protections:** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

## MATERIAL SAFETY DATA SHEET

Material Name: Epinephrine Solution for Injection  
Revision date: 19-Oct-2010

Page 3 of 6  
Version: 2.0

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

**General Handling:** Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**Storage Conditions:** Store as directed by product packaging.

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

#### Sodium bisulfite

|                                   |                         |
|-----------------------------------|-------------------------|
| ACGIH Threshold Limit Value (TWA) | 5 mg/m <sup>3</sup> TWA |
| Australia TWA                     | 5 mg/m <sup>3</sup>     |
| Belgium OEL - TWA                 | Listed                  |
| Denmark OEL - TWA                 | Listed                  |
| France OEL - TWA                  | Listed                  |
| Greece OEL - TWA                  | Listed                  |
| Ireland OEL - TWAs                | Listed                  |
| Portugal OEL - TWA                | Listed                  |
| Spain OEL - TWA                   | Listed                  |

#### Sodium chloride

|                     |        |
|---------------------|--------|
| Latvia OEL - TWA    | Listed |
| Lithuania OEL - TWA | Listed |

#### Epinephrine

**Pfizer Occupational Exposure Band (OEB):** OEB 4 - Skin (control exposure to the range of >1ug/m<sup>3</sup> to <10ug/m<sup>3</sup>, provide additional precautions to protect from skin contact)

#### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

#### Environmental Exposure Controls:

Refer to specific Member State legislation for requirements under Community environmental legislation.

#### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

# MATERIAL SAFETY DATA SHEET

Material Name: Epinephrine Solution for Injection  
Revision date: 19-Oct-2010

Page 4 of 6  
Version: 2.0

## 9. PHYSICAL AND CHEMICAL PROPERTIES

|                           |                |                          |                 |
|---------------------------|----------------|--------------------------|-----------------|
| <b>Physical State:</b>    | Liquid         | <b>Color:</b>            | Clear colorless |
| <b>Molecular Formula:</b> | Mixture        | <b>Molecular Weight:</b> | Mixture         |
| <b>Solubility:</b>        | Soluble: Water |                          |                 |
| <b>pH:</b>                | 2.2-5.0        |                          |                 |
| <b>Specific Gravity:</b>  | ~1             |                          |                 |

## 10. STABILITY AND REACTIVITY

|                                |  |
|--------------------------------|--|
| <b>Chemical Stability:</b>     | Stable under normal conditions of use.                             |
| <b>Conditions to Avoid:</b>    | Fine particles (such as dust and mists) may fuel fires/explosions. |
| <b>Incompatible Materials:</b> | As a precautionary measure, keep away from strong oxidizers        |

## 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### **Epinephrine**

Rat Dermal LD50 62 mg/kg  
Rat Oral LD50 30 mg/kg

#### **Sodium chloride**

Rat Oral LD50 3000 mg/kg  
Mouse Oral LD50 4000 mg/kg

### Irritation / Sensitization: (Study Type, Species, Severity)

#### **Sodium chloride**

Eye Irritation Rabbit Moderate  
Skin Irritation Rabbit Mild

### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### **Epinephrine**

|                            |        |              |                     |                 |                        |
|----------------------------|--------|--------------|---------------------|-----------------|------------------------|
| Embryo / Fetal Development | Rat    | Intravenous  | Dose not specified  | Not teratogenic |                        |
| Embryo / Fetal Development | Rabbit | Subcutaneous | 30 times human dose | LOAEL           | Developmental toxicity |
| Embryo / Fetal Development | Mouse  | Subcutaneous | 7 times human dose  | LOAEL           | Developmental toxicity |

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### **Epinephrine**

|                               |                                   |                              |
|-------------------------------|-----------------------------------|------------------------------|
| Bacterial Mutagenicity (Ames) | <i>Salmonella</i>                 | Negative                     |
| Sister Chromatid Exchange     |                                   | Negative with activation     |
| Sister Chromatid Exchange     | Chinese Hamster Ovary (CHO) cells | Equivocal without activation |

## MATERIAL SAFETY DATA SHEET

Material Name: Epinephrine Solution for Injection  
Revision date: 19-Oct-2010

Page 5 of 6  
Version: 2.0

### 11. TOXICOLOGICAL INFORMATION

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

**Sodium bisulfite**  
**IARC:** Group 3

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

**Epinephrine**  
**RCRA - P Series Wastes** Listed

### 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

**EU Indication of danger:** Not classified

**OSHA Label:**  
Non-hazardous in accordance with international standards for workplace safety.

#### Canada - WHMIS: Classifications

**WHMIS hazard class:**

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

**Epinephrine**

# MATERIAL SAFETY DATA SHEET

Material Name: Epinephrine Solution for Injection  
Revision date: 19-Oct-2010

Page 6 of 6  
Version: 2.0

## 15. REGULATORY INFORMATION

|   |                  |
|---|------------------|
| CERCLA/SARA Hazardous Substances and their Reportable Quantities: | 1000 lb final RQ |
| Inventory - United States TSCA - Sect. 8(b)                       | 454 kg final RQ  |
| Australia (AICS):   | Listed           |
| Standard for the Uniform Scheduling for Drugs and Poisons:        | Listed           |
| EU EINECS/ELINCS List   | Schedule 3       |
|   | Schedule 4       |
|   | 200-098-7        |

### Sodium bisulfite

|   |                  |
|---|------------------|
| CERCLA/SARA Hazardous Substances and their Reportable Quantities: | 2270 kg final RQ |
| Inventory - United States TSCA - Sect. 8(b)                       | 5000 lb final RQ |
| Australia (AICS):   | Listed           |
| EU EINECS/ELINCS List   | Listed           |
|   | 231-548-0        |

### Water for Injection

|   |           |
|---|-----------|
| Inventory - United States TSCA - Sect. 8(b)                     | Listed    |
| Australia (AICS):   | Listed    |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present   |
| EU EINECS/ELINCS List   | 231-791-2 |

### Sodium chloride

|   |           |
|---|-----------|
| Inventory - United States TSCA - Sect. 8(b) | Listed    |
| Australia (AICS):                           | Listed    |
| EU EINECS/ELINCS List                       | 231-598-3 |

## 16. OTHER INFORMATION

### Text of R phrases mentioned in Section 3

R31 - Contact with acids liberates toxic gas.  
R22 - Harmful if swallowed.  
R24/25 - Toxic in contact with skin and if swallowed.

**Data Sources:** Publicly available toxicity information. Pfizer proprietary drug development information.

**Reasons for Revision:** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 9 - Physical and Chemical Properties. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

**Prepared by:** Product Stewardship Hazard Communications  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**